PTC Therapeutics projects FY26 product revenue between $700M to $800M
Source: SeekingAlpha
2026-01-12 11:09:21 ET
More on PTC Therapeutics
- PTC Therapeutics downgraded at RBC as Sephience sales priced in
- Sandisk to join S&P 500; UPWK, FIBK, HBI to be part of S&P SmallCap 600
Read the full article on Seeking Alpha
For further details see:
PTC Therapeutics projects FY26 product revenue between $700M to $800M
PTC Therapeutics Inc.
NASDAQ: PTCT
PTCT Trading
2.78% G/L:
$64.075 Last:
260,373 Volume:
$63.91 Open:
PTCT Latest News
March 03, 2026 10:11:53 am
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
February 19, 2026 04:01:00 pm
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PTCT Stock Data
$5,800,830,036
75,872,448
1.06%
134
N/A
Biotechnology & Life Sciences
Healthcare
US
Warren
